FARN — Faron Pharmaceuticals Oy Share Price
Last trade - 00:00- £98.35m
- £103.62m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | n/a | ||
| Return on Equity | n/a | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | €m | n/a | n/a | n/a | n/a | n/a | n/a | 7 | -100% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Faron Pharmaceuticals Oy is a Finland-based clinical stage biopharmaceutical company. The company has three drug candidates all based on mastering immune modulation and, as a result, tackling unmet needs in cancer, preventing organ damage and treating blood count abnormalities. The Company's goal is to build future immunotherapy, i.e., to bring new treatments to patients by affecting the immune system. Faron’s drug candidate, Traumakine, is a drug developed by the Company to prevent multi-organ damage and excessive inflammatory responses. Another drug candidate, Haematokine, promotes the expansion of bone marrow stem cells. It is being developed, e.g., for the treatment of chemotherapyinduced neutropenia (CIN). In neutropenia patients have less blood cells called neutrophils than normal due to cancer treatment.
Directors
- Frank Armstrong NEC (64)
- Markku Jalkanen CEO (67)
- Matti Manner NVC (64)
- Toni Haenninen CFO
- Juho Jalkanen COO
- Anne Whitaker NED (54)
- Gregory Brown NID (67)
- John Poulos NID (67)
- Leopoldo Zambeletti NID (51)
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- October 24th, 2006
- Public Since
- November 17th, 2015
- No. of Employees
- 34
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- London Stock Exchange
- Shares in Issue
- 72,007,497
- Address
- Joukahaisenkatu 6, TURKU, 20520
- Web
- https://www.faron.com/
- Phone
- +358 24695151
- Auditors
- PricewaterhouseCoopers Oy
Latest News for FARN
Upcoming Events for FARN
Half Year 2024 Faron Pharmaceuticals Oy Earnings Release
Similar to FARN
4Basebio
London Stock Exchange
Allergy Therapeutics
London Stock Exchange
Arecor Therapeutics
London Stock Exchange
Avacta
London Stock Exchange
Batm Advanced Communications
London Stock Exchange
FAQ
As of Today at 20:36 UTC, shares in Faron Pharmaceuticals Oy are trading at 98.50p. This share price information is delayed by 15 minutes.
Shares in Faron Pharmaceuticals Oy last closed at 98.50p and the price had moved by -54.92% over the past 365 days. In terms of relative price strength the Faron Pharmaceuticals Oy share price has underperformed the FTSE All Share Index by -59.31% over the past year.
The overall consensus recommendation for Faron Pharmaceuticals Oy is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Faron Pharmaceuticals Oy does not currently pay a dividend.
Faron Pharmaceuticals Oy does not currently pay a dividend.
Faron Pharmaceuticals Oy does not currently pay a dividend.
To buy shares in Faron Pharmaceuticals Oy you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of 98.50p, shares in Faron Pharmaceuticals Oy had a market capitalisation of £70.93m.
Here are the trading details for Faron Pharmaceuticals Oy:
- Country of listing: United Kingdom
- Exchange: LSE
- Ticker Symbol: FARN
Based on an overall assessment of its quality, value and momentum Faron Pharmaceuticals Oy is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Faron Pharmaceuticals Oy is 126.87p. That is 28.8% above the last closing price of 98.50p.
Analysts covering Faron Pharmaceuticals Oy currently have a consensus Earnings Per Share (EPS) forecast of -€0.28 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Faron Pharmaceuticals Oy. Over the past six months, its share price has underperformed the FTSE All Share Index by -62.78%.
As of the last closing price of 98.50p, shares in Faron Pharmaceuticals Oy were trading -49.21% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Faron Pharmaceuticals Oy PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at 98.50p.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Faron Pharmaceuticals Oy's management team is headed by:
- Frank Armstrong - NEC
- Markku Jalkanen - CEO
- Matti Manner - NVC
- Toni Haenninen - CFO
- Juho Jalkanen - COO
- Anne Whitaker - NED
- Gregory Brown - NID
- John Poulos - NID
- Leopoldo Zambeletti - NID